- Home
- PLUR vs RDI Comparison
PLUR vs RDI Comparison
Compare PLUR & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- RDI
- Stock Information
- Founded
- PLUR 2001
- RDI 1937
- Country
- PLUR Israel
- RDI United States
- Employees
- PLUR N/A
- RDI N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- RDI Movies/Entertainment
- Sector
- PLUR Health Care
- RDI Consumer Discretionary
- Exchange
- PLUR Nasdaq
- RDI Nasdaq
- Market Cap
- PLUR 36.9M
- RDI 31.3M
- IPO Year
- PLUR N/A
- RDI N/A
- Fundamental
- Price
- PLUR $3.90
- RDI $1.39
- Analyst Decision
- PLUR Strong Buy
- RDI
- Analyst Count
- PLUR 1
- RDI 0
- Target Price
- PLUR $12.00
- RDI N/A
- AVG Volume (30 Days)
- PLUR 11.1K
- RDI 22.5K
- Earning Date
- PLUR 11-11-2025
- RDI 11-12-2025
- Dividend Yield
- PLUR N/A
- RDI N/A
- EPS Growth
- PLUR N/A
- RDI N/A
- EPS
- PLUR N/A
- RDI N/A
- Revenue
- PLUR $1,336,000.00
- RDI $219,213,000.00
- Revenue This Year
- PLUR $97.38
- RDI $6.85
- Revenue Next Year
- PLUR $293.97
- RDI $10.86
- P/E Ratio
- PLUR N/A
- RDI N/A
- Revenue Growth
- PLUR 309.82
- RDI 7.59
- 52 Week Low
- PLUR $3.33
- RDI $1.17
- 52 Week High
- PLUR $7.13
- RDI $1.87
- Technical
- Relative Strength Index (RSI)
- PLUR 41.43
- RDI 43.09
- Support Level
- PLUR $3.60
- RDI $1.41
- Resistance Level
- PLUR $4.00
- RDI $1.51
- Average True Range (ATR)
- PLUR 0.19
- RDI 0.06
- MACD
- PLUR -0.01
- RDI -0.00
- Stochastic Oscillator
- PLUR 29.70
- RDI 25.00
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.